INDIA New England News New York– Researchers have uncovered a potential new way to target pancreatic tumours that express high intratumooural interferon signalling (IFN). The team found that high type I IFN signalling is present in a subset of pancreatic tumours and it triggers a decrease in the level of nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide hydrogen (NADH) in pancreatic cancer cells, which are vital cofactors in critical metabolic processes. “This is a study that identifies a potential vulnerability created by type I IFNs in pancreatic cancer that can be leveraged for what appears to be an effective therapeutic strategy,” said researcher Timothy Donahue from the University of California – Los Angeles, in a mice-based study.